skip to main
|
skip to sidebar
生技
Monday, October 19, 2009
Targacept:AZN计划进一步开发AZD3480
2009/07/09
Targacept宣布,大型药厂AstraZeneca (AZN)通知TRGT,AZN计划进一步开发AZD3480 (TC-1734),这种药物可能治疗注意力不足过动症(AD/HD),并同意支付1000万美元里程碑款项给TRGT。AZN也证实,计画继续开发AZD1446 (TC-6683),治疗老年失智症,AZD1446目前进行第一阶段实验,透过双方合作研究发现这种新药。
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
Resources
关注榜
生物谷
汤姆森科技信息
新药发展动态
fiercebiotech
EP Vantage
gekkowire
Labels
ALTH
(1)
AMGN
(1)
AMLN
(1)
AMRN
(1)
ARIA
(2)
ARNA
(1)
ATHX
(1)
AVEO
(1)
AVNR
(1)
BIIB
(1)
CHPI
(1)
CLDX
(3)
CMED
(1)
CSKI
(1)
DNDN
(7)
EXEL
(2)
HALO
(3)
HGSI
(5)
HLCS
(6)
ICGN
(1)
IMGN
(1)
IMMU
(2)
INCY
(15)
ISPH
(2)
ITMN
(4)
JGBO
(1)
KERX
(2)
MITI
(2)
MNKD
(4)
MYGN
(1)
NKBP
(2)
NYMX
(4)
ONTY
(1)
ONXX
(1)
OPK
(1)
OREX
(2)
PARD
(1)
PRE/VIEW
(2)
RIGL
(2)
SCR
(1)
SGEN
(11)
SPPI
(1)
SVA
(1)
TRGT
(9)
TTNP.PK
(1)
VNDA
(1)
VPHM
(2)
VRTX
(2)
VVUS
(7)
WATCHLIST
(2)
XNPT
(4)
XOMA
(1)
ZGEN
(2)
Search This Blog
Blog Archive
►
2011
(16)
►
May
(1)
►
April
(9)
►
March
(3)
►
January
(3)
►
2010
(35)
►
December
(6)
►
September
(1)
►
July
(6)
►
June
(2)
►
May
(7)
►
April
(3)
►
March
(4)
►
February
(1)
►
January
(5)
▼
2009
(55)
►
December
(9)
►
November
(2)
▼
October
(22)
Targacept - my favorite biotech idea into the new ...
2015年多动腿综合症药物市场将超过10亿美元
XenoPort's Most Recent Data Points to Larger Oppor...
Targacept target raised to $34 from $26 at Oppenhe...
抑郁药TC-5214一项2b期试验获肯定结果
Targacept:AZN计划进一步开发AZD3480
ADHD在研药AZD3480中期临床实验表现良好
不宁腿综合征药XP13512将在日本申请上市
Xenoport:发表第二阶段临床实验结果为正面
Helicos BioSciences接获NIH两年期合约
诺华收购Vanda制药的精神分裂症药物的销售权
Nymox Announces New Pooled Analysis Confirms 12 Mo...
Halozyme Therapeutics, Inc.Additional Data from Ph...
90% 以上的精神分裂症患者毕生都会发生激越。发生激越的患者中,约有70%每年会发作1到6次。Ale...
Micromet
Smaller companies win in most valuable race June ...
全球最有药物价值排行榜
B细胞药物:靶向系统性红斑狼疮
美国审批速度加快 专利药断层期有望平稳度过
Lupus 狼疮
一则散发着乡土气息的幽默药品广告案例 Halozyme治疗公司推出了一个重组酶制剂(商品名为c...
From The Garage To The Biotech Fast Track
►
September
(20)
►
June
(1)
►
March
(1)
Followers
No comments:
Post a Comment